Nevertheless, future research could validate ICA1L as a biomarker through longitudinal studies assessing its levels in cerebrospinal fluid and blood, investigating its ability to cross the blood–brain barrier, and characterizing how it correlates with dementia-related outcomes [36,37,38,39]. This evidence concerns the gene ICA1L and dementia.